Jushi Holdings (JUSHF) Liabilities and Shareholders Equity (2021 - 2026)
Jushi Holdings (JUSHF) reported Liabilities and Shareholders Equity of $435.1 million for Q1 2026, little changed year-over-year from $433.6 million in Q1 2025, and up 3.03% quarter-over-quarter from $422.3 million in Q4 2025.
Jushi Holdings (JUSHF) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $435.1 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $435.1 million, changed 0.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 2.82% YoY), and the FY2025 annual result was $422.3 million, down 4.08% from the prior year.
- Liabilities and Shareholders Equity advanced to $435.1 million in Q1 2026 per JUSHF's latest filing, from $422.3 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $710.8 million in Q2 2022 and troughed at $422.3 million in Q4 2025.
- A 5-year average of $499.4 million and a median of $457.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity retreated 29.44% in 2023, then advanced 0.35% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $529.3 million in 2022, then decreased by 12.46% to $463.4 million in 2023, then dropped by 4.98% to $440.3 million in 2024, then declined by 4.08% to $422.3 million in 2025, then increased by 3.03% to $435.1 million in 2026.
- Business Quant data shows JUSHF's Liabilities and Shareholders Equity at $435.1 million in Q1 2026, $422.3 million in Q4 2025, and $431.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | Jushi Holdings | - | - | 29.88 Mn | 435.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435.14 Mn |
| Dec 31, 2025 | 422.34 Mn |
| Sep 30, 2025 | 431.70 Mn |
| Jun 30, 2025 | 432.37 Mn |
| Mar 31, 2025 | 433.62 Mn |
| Dec 31, 2024 | 440.32 Mn |
| Sep 30, 2024 | 442.33 Mn |
| Jun 30, 2024 | 455.23 Mn |
| Mar 31, 2024 | 457.85 Mn |
| Dec 31, 2023 | 463.40 Mn |
| Sep 30, 2023 | 488.67 Mn |
| Jun 30, 2023 | 501.49 Mn |
| Mar 31, 2023 | 520.04 Mn |
| Dec 31, 2022 | 529.34 Mn |
| Sep 30, 2022 | 665.41 Mn |
| Jun 30, 2022 | 710.77 Mn |
| Mar 31, 2022 | 659.55 Mn |
| Dec 31, 2021 | 652.05 Mn |